BioAtla, Beijing Sinobioway expand CAB deal

BioAtla LLC (San Diego, Calif.) and Beijing Sinobioway Group Ltd. (Beijing, China) added five products from BioAtla's Conditionally Active Biologic (CAB) platform to a 2015 deal granting Sinobioway exclusive rights to develop and commercialize similar products in Taiwan and China, including Hong Kong and Macau.

BioAtla will receive $5 million up front, $25 million upon approval of an IND for the first program, and up to $40 million after Sinobioway selects the remaining four candidates. BioAtla will also receive $20 million in credits for services performed by Sinobioway...